Particularly, hsa-miR-181a-5p was reported to target the tumor suppressor Wnt inhibitory factor 1 (WIF-1) and has been linked to tumor growth, liver metastasis and poorer overall survival in CRC [10,11] Moreover, hsa-miR-181a-5p was proven to promote angiogenesis in both in vitro and in vivo assays by indirectly activating the SRC kinase/Vascular Endothelial Growth Factor (SRC/VEGF) pathway [12]. This evidence concerns the gene VEGFA and neoplasm.